Encompass Health

EHC on NYSE. Encompass Health runs inpatient rehabilitation hospitals for people recovering from injury or illness. Market value $11.9bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

The company doesn't report operating profit, so we work it out from pre-tax profit and interest.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
3.4%fair

For every $100 of what the whole company costs, it produced $3.36 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
12.9×fair

You pay 12.9 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
13.8%five-year median

Each dollar kept in the business earns 14 cents a year. Above 10 is good.

Quality score: 98 of 100. Price score: 78 of 100. Our list needs 70 on quality and 60 on price.

$124.69 a share, 34% above its 1-year low

Over the past year the price has ranged from $92.77 to $127.99.

Dividend: 0.6% a year

Paid every year for at least 5 years

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.2
0.1
0.3
0.4
0.4
0.4
2021202220232024202512 monthsto Jun '26
Revenue
$4.0bn$4.3bn$4.8bn$5.4bn$5.9bn
Operating margin
13.9%12.4%15.6%16.5%18.1%
Debt to equity
1.722.111.651.211.02
Shares outstanding
0.10bn0.10bn0.10bn0.10bn0.10bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)7 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • Debt1.02× equity
  • Revenue growth, five yearsStrong, 10.7% a year
  • Buying back its own sharesRoughly flat

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.6 billion last quarter, up 10% on a year ago.
  • Profit: $154 million, up 8% on a year ago.
  • Spare cash over the past 12 months: $413 million, down from $439 million.
  • 2% fewer shares than a year ago. Each share owns a bit more of the company.
  • Debt is $2.5 billion more than cash, up from $2.4 billion a year ago.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$1.4bn
December 2024$1.4bn
March 2025$1.5bn
June 2025$1.5bn
September 2025$1.5bn
December 2025$1.5bn
March 2026$1.6bn
June 2026$1.6bn
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$108m
December 2024$121m
March 2025$152m
June 2025$142m
September 2025$127m
December 2025$146m
March 2026$195m
June 2026$154m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
6 November 2026

Who owns it

4 long-term investors we follow own it, unchanged from 4 last quarter. 597 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $48m.

  • Price Andrew L
    Chief Accounting Officer
    Sold
    Date
    31 August 2026
    Shares
    5,211
    Price
    $120.93
    Value
    $630,166
  • Darby John Patrick
    EVP, Gen Counsel & Secretary
    Sold
    Date
    31 August 2026
    Shares
    4,858
    Price
    $121.09
    Value
    $588,255
  • COLTHARP DOUGLAS E
    EVP & Chief Financial Officer
    Sold
    Date
    10 August 2026
    Shares
    18,869
    Price
    $125.38
    Value
    $2m
  • Tarr Mark J
    President & CEO, Director
    Sold
    Date
    10 August 2026
    Shares
    173,148
    Price
    $125.47
    Value
    $22m
  • Darby John Patrick
    EVP, Gen Counsel & Secretary
    Sold
    Date
    10 August 2026
    Shares
    8,906
    Price
    $125.95
    Value
    $1m
  • COLTHARP DOUGLAS E
    EVP & Chief Financial Officer
    Sold
    Date
    15 May 2026
    Shares
    27,694
    Price
    $106.83
    Value
    $3m
  • Tuer Patrick William
    EVP, Chief Operating Officer
    Sold
    Date
    11 May 2026
    Shares
    682
    Price
    $104.56
    Value
    $71,310
  • Fay Edmund
    Sr. Vice Pres. and Treasurer
    Sold
    Date
    9 March 2026
    Shares
    11,937
    Price
    $107.00
    Value
    $1m
  • Tarr Mark J
    President & CEO, Director
    Sold
    Date
    11 February 2026
    Shares
    150,000
    Price
    $111.64
    Value
    $17m
  • Tuer Patrick William
    EVP, Chief Operating Officer
    Sold
    Date
    10 February 2026
    Shares
    2,804
    Price
    $107.62
    Value
    $301,766

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 7 Aug 2026 and 7 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.

    Could happen
    We receive state directed and supplemental payments in connection with several state Medicaid programs. In 2025, those payments totaled approximately $148 million. We also pay provider taxes to fund, in part, state Medicaid programs, and in 2025 those payments totaled approximately $127 million. In May 2024, CMS issued a final rule related to Medicaid managed care programs that addresses state directed payment programs and imposes new requirements for these programs. The various elements of the rule take effect between its issuance and early 2028. Ultimately, this rule could result in significant changes to state directed and supplemental payment programs from which we receive payments. However, a federal district court recently vacated portions of this rule following a legal challenge by the state of Texas. CMS appealed the decision, but the court enjoined enforcement of this rule while the appeal is pending. The OBBBA also contains provisions limiting states’ ability to assess provider taxes to increase federal matching Medicaid funds and make directed payments to providers. Most of these provisions take effect in 2027 or later and likely require additional federal and state regulatory action to implement.
    Read more
  • Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.

    Could happen
    It is possible that additional rulemaking could result in significant restructurings of existing state Medicaid programs, including provider tax and related directed and supplemental payment programs. State authorities design the structures and operations of these programs to promote access to acute-care hospitals for Medicaid patients by supplementing acute-care reimbursement. Historically, we are not aware of any IRFs playing a significant role in the design given the limited number of IRF Medicaid patients, so we are uncertain what attention state authorities will give to the effects of additional rulemaking on IRFs. We are unable to estimate the financial impact that structural modifications and other program changes, if any, may have on our Medicaid provider tax expenses or directed and supplemental payments. We cannot be certain that changes to state directed and supplemental payment programs will directly correspond to changes in the related provider taxes. CMS periodically assesses the compliance of these programs, and CMS’s determination that a state’s program fails to comply may result in a decrease in state directed and supplemental payments and recoupment of prior payments under that state’s noncompliant program.
    Read more
  • Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues and profitability.

    Could happen
    Medicare Advantage plans may use overly restrictive coverage determinations in the pre-authorization process to limit participating members’ access to needed inpatient rehabilitative care. Medicare Advantage plans must provide coverage for inpatient rehabilitative care to the extent conventional Medicare does. However, in our experience, Medicare Advantage plans frequently deny coverage for inpatient rehabilitative care when the patients would have qualified for that care under conventional Medicare rules. Additionally, large Medicare Advantage plans have acquired home health operators. Those Medicare Advantage plans may attempt to shift patients who would benefit from intensive inpatient rehabilitation to home health in order to reduce costs to the plans in the near term.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.